Navigation Links
deCODE genetics Announces First Quarter 2008 Financial Results
Date:5/1/2008

e in genotyping and data management. In the past three months,

subscribers have received updates on novel genetic factors involved in

prostate cancer, breast cancer, nicotine addiction and lung cancer,

osteoporosis, intracranial and abdominal aortic aneurysm, and human

fertility and evolution.

-- Heart attack - DG051. In January, the company announced positive

results from its Phase IIa clinical testing of DG051, deCODE's

developmental compound for the prevention of heart attack. DG051,

discovered by deCODE chemists, is designed to counter risk of heart

attack by reining in the activity of the leukotriene pathway, reducing

the production of the pro-inflammatory molecule leukotriene B4 (LTB4).

The results of the Phase IIa study confirmed that DG051 delivers

significant dose-dependent reductions in LTB4 in patients with a

history of heart attack or coronary artery disease and who were taking

a variety of concomitant medications. The pharmacokinetic and safety

profiles of the compound were favorable and similar to those seen in

previous studies in healthy volunteers. The company is actively seeking

a partner with whom to take the next steps in development of its

leukotriene program.

-- Arterial thrombosis: DG041. DG041 is deCODE's novel, first-in-class

antagonist of the EP3 receptor for prostaglandins E2, being developed

as a next-generation oral anti-platelet therapy for preventing arterial

thrombosis without increasing bleeding time. In clinical studies to

date, DG041 has been shown to dramatically inhibit platelet aggregation

as well as platelet activation mediated specifically through

vasodilator-stimulated phosphoprotein (VASP), a biomarker useful for

measuring platelet activity. These effects have been shown to be

concentration-
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
2. deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information
3. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
4. U.S. Preventive Medicine and deCODE Genetics Sign Letter of Intent to Expand Personalized Medicine Platform
5. A Smoking Gene: deCODE Shows How a Single Variant in the Sequence of the Genome Confers Nicotine Dependence and Risk of Lung Cancer and Other Disease
6. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
7. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
8. deCODE Genetics Announces Full-year 2007 Financial Results
9. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
10. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
11. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ELLYN, Ill. , July 2, 2015 ... Colton Eakins are gaining invaluable real-world experiences ... of Technology this summer. The students will ... Dr. Jeff Wereszczynski,s research group at IIT. The ... Dr. Tom Carter , Physics; Dr. Kathy ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Sleepless nights ... an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers ... voice command technology makes it effortless to use, while the integration of the Bluetooth ...
(Date:7/1/2015)... PARK, N.C. and PARIS ... research firm AgBiome, and Genective, key developer of ... accelerate the discovery of new generations of insect ... for insect control to counter the realities of ... with Genective, aligning AgBiome,s unique insect control technology ...
(Date:7/1/2015)... and BANGALORE, India , ... genomic profiling company that uses next generation sequencing technology ... Scott A. Storrer as chief executive officer. ... he will be responsible for all strategy, business expansion ... , who has served as Strand,s chairman and CEO ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... Oct. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... covering interim results from a U.K. Phase ... advanced or,metastatic cancers is scheduled to be ... Molecular Targets and Cancer Therapeutics in,San Francisco. ...
... 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... letter of approval from the U.K. Medicines ... Clinical Trial Application (CTA) to begin,a clinical ... with cyclophosphamide, a chemotherapeutic agent as well ...
... Forecast Raised $.05 to $2.25 to $2.35., ST. LOUIS, Oct. 23 ... are to comparable periods in 2006):, -- Strongest Quarterly ... improved on prior quarters, performance, with reported quarterly ... matched the record high sales achieved in ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 2Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 4Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 5Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 6Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 7Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 8Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 9Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 10Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 11Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 12Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 13Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 14Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 15Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 16Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 17Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 18Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 19Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 20
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... December 10, 2008 - (BRONX, NY) - Researchers at ... found that overactivity of a brain enzyme may play ... The findings were reported in Cell Metabolism . ... disease, many scientists have focused on the hypothalamus, an ...
... season, think twice about spending money on a commercial ... methodkeeping your tree in a container of fresh wateris ... and healthy. Researchers have determined that some flame retardants ... several cases the chemical retardants sped up the drying ...
... Salmonella typhimurium employ a startling array of ... and produce illness. Through their expression of ... ingeniously adapt to varied environments, modifying their disease-causing ... study of a broad range of microbial virulence ...
Cached Biology News:Brain enzyme may play key role in controlling appetite and weight gain 2Flame retardants prove ineffective on fresh-cut Christmas trees 2The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 2The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 3The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 4The medium is the message: Manipulating salmonella in spaceflight curtails infectiousness 5
... MetaVue Imaging System is the cost-effective solution ... commands tailored to common research imaging tasks, ... analysis and simple image analysis. Compatibility ... library means that MetaVue has the power ...
Sterile, Cell culture tested...
... Although there have been many modifications to ... defined media, salt solutions still play an important ... to maintain the pH and osmotic balance in ... water and essential inorganic ions, is as valuable ...
A substrate for all AChE-based EIA kits....
Biology Products: